-
-
-
-
-
-
-
Jasper Therapeutics (JSPR) Misses Q4 EPS by 32c
-
-
-
-
-
-
-
Jasper Therapeutics (JSPR) PT Lowered at RBC Capital as 'BEACON Investigation Raises Further Questions'
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Jasper Therapeutics (JSPR)
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Jasper Therapeutics (JSPR)
-
-
-
-
-
-
-
Jasper Therapeutics (JSPR) Files $200M Mixed Shelf
-
-
-
-
-
-
-
Jasper Therapeutics (JSPR) PT Lowered to $48 at RBC Capital; Stock Pressured Following BEACON's Initial Data
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on Jasper Therapeutics (JSPR)
-
435,117 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

